Medical Treatment & Drug Development
Post-Doctoral Fellowships
Israel
Studying multi-drug resistance implications of the 'excludon', a novel antisense-based regulatory structure in bacteria
Getting the Better of Antibiotic Resistance
To add or modify information on this page, please contact us at the following address: community.research@axa.com

Ofir
COHEN
Institution
Weizmann Institute of Science
Country
Israel
Nationality
Israeli
Related articles
Chronic & Non-communicable Diseases
Medical Treatment & Drug Development
AXA Project
France
Pain Pediatric & Elderly AXA Research Lab (PEARL)
Cutaneous neuropathic pain is a highly debilitating chronic condition, characterized by persistent sensations of burning, tingling, or hypersensitivity. It disproportionately... Read more
Celine
GRECO
Hôpital Necker-Enfants Malades
Medical Treatment & Drug Development
Mécénat des Mutuelle
France
Accelerating drug innovation with the Euridis school and its DDD Challenge
The project addresses a dual challenge: on one hand, the increasing complexity of drug development, which requires a thorough understanding... Read more

Laurence
SABATIER
Institut du médicament de Strasbourg
Medical Treatment & Drug Development
Mécénat des Mutuelle
France
New Molecule to Combat Antibiotic-Resistant Childhood Sepsis
The global spread of antibiotic resistance requires the identification of new bacterial drug targets, the design and synthesis of innovative... Read more

Nalini
RAMA RAO